Lyell Immunopharma (NASDAQ:LYEL) Share Price Breaks Below 50 Day Moving Average – What’s Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s share price passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $10.85 and traded as low as $10.58. Lyell Immunopharma shares last traded at $10.77, with a volume of 78,055 shares.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LYEL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. B. Riley Financial started coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 target price on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, October 25th. Finally, Royal Bank Of Canada set a $34.00 target price on shares of Lyell Immunopharma in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lyell Immunopharma has an average rating of “Moderate Buy” and an average target price of $40.86.

Lyell Immunopharma Price Performance

The company has a market cap of $263.87 million, a P/E ratio of -0.84 and a beta of -0.04. The stock has a 50-day moving average of $10.85 and a 200 day moving average of $16.77.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.94) by $0.02. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. Sell-side analysts predict that Lyell Immunopharma, Inc. will post -7.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its holdings in shares of Lyell Immunopharma by 194.8% in the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after purchasing an additional 76,921 shares in the last quarter. Opaleye Management Inc. increased its stake in shares of Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after purchasing an additional 264,928 shares during the last quarter. venBio Partners LLC acquired a new position in shares of Lyell Immunopharma during the 2nd quarter worth $4,744,643. Dimensional Fund Advisors LP acquired a new position in shares of Lyell Immunopharma during the 1st quarter worth $959,000. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma during the 1st quarter worth $445,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.